Table 3.
Success rate of primary eradication therapy for Helicobacter pylori infection with PPI and P-CAB between January 2015 and March 2016
| PPIs |
P-CAB |
||||
|---|---|---|---|---|---|
| omeprazole | rabeprazole | lansoprazole | esomeprazole | vonoprazan | |
| No. of total patients | 269 | 19,236 | 18,339 | 4,984 | 31,171 |
| Proportion of each treatment, % | 0.4 | 26.0 | 24.8 | 6.7 | 42.1 |
| No. of failed patients | 52 | 04,308 | 3,740 | 899 | 2,889 |
| Success rate, % | 80.7 | 77.6 | 79.6 | 82.0 | 90.7 |
| 95% CI, % | 76.0–85.4 | 77.0–78.2 | 79.0–80.2 | 80.9–83.0 | 90.4–91.1 |
| Success rate in clinical trials1, % (n) | 78.8 (19) | 85.7–89.0 (28) | 83.7–91.1 (29) | − | 92.6 (20) |
1
Data in clinical trials used for the development of information written in the package insert in Japan.
P-CAB, potassium-competitive acid blocker; PPIs, proton pump inhibitors.